CLAIMS

- 1. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and:
 - (a) an inhibitor of the RSV fusion protein; and
 - (b) a benzodiazepine derivative capable of inhibiting RSV replication.
- 2. A composition according to claim 1, wherein component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,

$$(R^3)_n \xrightarrow{R^2} O$$

$$N \xrightarrow{N} R^5$$

$$(V)$$

wherein:

5

10

- R^1 represents C_{1-6} alkyl, aryl or heteroaryl;
- R² represents hydrogen or C₁₋₆ alkyl;
- each R³ is the same or different and represents halogen, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, amino, mono(C₁₋₆ alkyl)amino, di(C₁₋₆ alkyl)amino, nitro, cyano, -CO₂R′, -CONR′R″, -NH-CO-R′, -S(O)R′, -S(O)₂R′, -NH-S(O)₂R′, -S(O)NR′R″ or -S(O)₂NR′R″, wherein each R′ and R″ is the same or different and represents hydrogen or C₁₋₆ alkyl;
- 20 n is from 0 to 3;
 - R⁴ represents hydrogen or C₁₋₆ alkyl:
 - R⁵ represents C₁₋₆ alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-, heterocyclyl-(C₁₋₆ alkyl)-, aryl-(C₁₋₆ hydroxyalkyl)-, carbocyclyl-(C₁₋₆ hydroxyalkyl)-, heterocyclyl-(C₁₋₆ hydroxyalkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR⁶;

- X represents -CO-, -S(O)- or -S(O)₂-; and
- R⁶ represents C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)-O-, heteroaryl-(C₁₋₆ alkyl)-O-, carbocyclyl-(C₁₋₆ alkyl)-O-, heterocyclyl-(C₁₋₆ alkyl)-O- or -NR[']R^{''} wherein each R['] and R^{''} is the same or different and represents hydrogen, C₁₋₆ alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆ alkyl)- or heterocyclyl-(C₁₋₆ alkyl)-.
- 10 3. A composition according to claim 2 wherein:

5

- each R³ is the same or different and represents halogen, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, amino, mono(C₁₋₆ alkyl)amino, di(C₁₋₆ alkyl)amino, nitro, cyano, -CO₂R', -CONR'R", -NH-CO-R', -S(O)R', -S(O)₂R', -NH-S(O)₂R' or -S(O)NR'R", wherein each R' and R" is the same or different and represents hydrogen or C₁₋₆ alkyl;
- R^5 represents C_{1-6} alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl- $(C_{1-6}$ alkyl)-, heteroaryl- $(C_{1-6}$ alkyl)-, carbocyclyl- $(C_{1-6}$ alkyl)-, heterocyclyl- $(C_{1-6}$ alkyl)- or -XR⁶;
- X represents -CO-, -S(O)- or -S(O)₂-; and
- R⁶ represents C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl,

 20 carbocyclyl, heterocyclyl, aryl-(C₁₋₆ alkyl)-, heteroaryl-(C₁₋₆ alkyl)-, carbocyclyl-(C₁₋₆

 alkyl)-, heterocyclyl-(C₁₋₆ alkyl)- or -NR'R" wherein each R' and R" is the same or

 different and represents hydrogen, C₁₋₆ alkyl, carbocyclyl, heterocyclyl, aryl,

 heteroaryl, aryl-(C₁₋₆ alkyl)- or heteroaryl-(C₁₋₆ alkyl)-.
- 4. A composition according to either claim 2 or claim 3, wherein R^1 is C_{1-2} alkyl or aryl.
 - 5. A composition according to any one of claims 2 to 4 wherein R² is hydrogen.
- 6. A composition according to any one of claims 2 to 5 wherein R³ is halogen,
 30 hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, amino, mono(C₁₋₄ alkyl)amino or di(C₁₋₄ alkyl)amino.

WO 2005/089769

PCT/GB2005/001018

7. A composition according to claim 6, wherein R^3 is fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkylthio, C_{1-2} haloalkyl, C_{1-2} haloalkoxy, amino, mono(C_{1-2} alkyl)amino or di (C_{1-2} alkyl)amino.

5

- 8. A composition according to any one of claims 2 to 7 wherein \mathbb{R}^4 is hydrogen or \mathbb{C}_{1-2} alkyl.
- 9. A composition according to any one of claims 2 to 8 wherein R⁵ is C₁₋₆ alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₄ alkyl)-, heteroaryl-(C₁₋₄ alkyl)-, carbocyclyl-(C₁₋₄ alkyl)-, heterocyclyl-(C₁₋₄ alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR⁶.
- 10. A composition according to claim 9, wherein R⁵ is C₁₋₄ alkyl, aryl, heteroaryl,
 15 carbocyclyl, heterocyclyl, phenyl-(C₁₋₂ alkyl)-, heteroaryl-(C₁₋₂ alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR⁶.
- 11. A composition according to claim 10, wherein R⁵ is C₁₋₄ alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl,
 20 phenyl-CH₂-, furanyl-CH₂-, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or -XR⁶.
 - 12. A composition according to any one of claims 2 to 11 wherein X is -CO- or -S(O)₂-.
- 13. A composition according to any one of claims 2 to 12 wherein, when R⁶ is a group NR'R" wherein each R' and R" is the same or different and represents hydrogen, C₁₋₄ alkyl, aryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₄ alkyl)- or heteroaryl-(C₁₋₄ alkyl)-.
 - 14. A composition according to claim 13, wherein when R^6 is a group -NR'R" each R' and R" is the same or different and represents hydrogen, C_{1-4} alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-CH₂-.

- 15. A composition according to claim 14, wherein when R^6 is a group -NR'R'' and one of R' and R'' is hydrogen.
- 16. A composition according to any one of claims 2 to 15 wherein R⁶ is C₁₋₆ alkyl,
 5 hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C₁₋₄ alkyl)-, heteroaryl-(C₁₋₄ alkyl)-, carbocyclyl-(C₁₋₄ alkyl)-, aryl-(C₁₋₄ hydroxyalkyl)-, carbocyclyl-(C₁₋₄ hydroxyalkyl)-, heterocyclyl-(C₁₋₄ hydroxyalkyl)-, aryl-(C₁₋₄ alkyl)-O-, heteroaryl-(C₁₋₄ alkyl)-O-, carbocyclyl-(C₁₋₄ alkyl)-O-, heterocyclyl-(C₁₋₄ alkyl)-O-, or -NR⁷R^{7/7}.
 - 17. A composition according to claim 16, wherein R^6 is C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, aryl, heteroaryl, carbocyclyl, heterocycly, phenyl- $(C_{1-2}$ alkyl)-, phenyl- $(C_{1-2}$ alkyl)-, heteroaryl- $(C_{1-2}$ alkyl)-, phenyl- $(C_{1-2}$ hydroxyalkyl)-, heteroaryl- $(C_{1-2}$ hydroxyalkyl)- or -NR'R''.
 - 18. A composition according to claim 17, wherein R⁶ is C₁₋₄ alkyl, C₁₋₄ alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C₁₋₂ alkyl)-, phenyl-CH₂-CH(OH)-, phenyl-CH₂-CH(OH)-, phenyl-CH₂-, phenyl-(C₁₋₂ alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or -NR[']R^{''}.
 - 19. A composition according to any one of the claims 2 to 18 wherein the benzodiazepine derivative of formula (V) is a benzodiazepine derivative of formula (Va):

$$(R^3)_n \xrightarrow{H} O$$

$$N = R^5$$

$$R^1$$

$$(Va)$$

wherein:

10

15

20

- R¹ is phenyl or methyl;
- R³ is methyl or chlorine;
- n is 0 or 1;

10

15

20

25

- R⁴ is hydrogen or methyl;
- 5 R⁵ is phenyl-CH₂-, furanyl-CH₂-, thienyl-C(O)-C(O)- or -XR⁶;
 - $X \text{ is -CO- or -S(O)}_2$ -; and
 - R⁶ is C₁₋₄ alkyl, C₁₋₄ alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C₁₋₂ alkyl)-, phenyl-CH₂-CH(OH)-phenyl-CH(OH)-CH₂-, phenyl-(C₁₋₂ alkyl)-O-, 1H-benzo[d]imidazol-2(3H)-onyl or -NR[']R^{''} wherein each R['] and R^{''} is the same or different and represents hydrogen, C₁₋₄ alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH₂)-, the phenyl moiety in the group R¹ being unsubstituted or substituted by a single fluorine, chlorine, C₁₋₂ alkyl, C₁₋₂ alkoxy, C₁₋₂ alkylthio, C₁₋₂ haloalkyl or C₁₋₂ haloalkoxy substituent;

the aryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, $C_{1.4}$ alkyl, $C_{2.4}$ acyl, hydroxy, $C_{1.4}$ alkoxy, $C_{1.4}$ alkylthio, $C_{1.4}$ haloalkyl, $C_{1.4}$ haloalkoxy, amino, mono($C_{1.4}$ alkyl)amino, di($C_{1.4}$ alkyl)amino, nitro, $-CO_2R^7$, $-S(O)_2R^7$ and $-S(O)_2NH_2$, wherein R^7 represents $C_{1.2}$ alkyl;

the heteroaryl moieties in the groups R^5 and R^6 being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-2} alkyl, C_{1-2} haloalkyl and $di(C_{1-2}$ alkyl)amino; and

the heterocyclyl and carbocyclyl moieties in the R^6 group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl and nitro.

- 20. A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is:
- 30 Cyclohexanecarboxylic acid 2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

- 3-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 4-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 5 2-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-trifluoromethylbenzamide;
 - N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - Thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-3-amide;

10

15

20

- Furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- Piperidine-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;
- Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;
 - 4-Nitro- N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - $3\text{-Nitro-}\ N\text{-}(2\text{-}oxo\text{-}5\text{-}phenyl\text{-}2,3\text{-}dihydro\text{-}1H\text{-}benzo[e][1,4]} diazepin\text{-}3\text{-}yl)\text{-}benzamide;$
- 4-Methyl-piperazine-1-carboxylic acid -(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- 3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-trifluoromethylbenzamide;
- 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 30 2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;

- 2-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide;
- (S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide

5

15

25

Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-amide;

- 2,3-Dihydro-benzofuran-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1Hbenzo[e][1,4]diazepin-3-yl)-amide;
- 10 Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-amide;

Thiophen-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-isonicotinamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)methanesulfonamide;

20 Propane-1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3yl)-amide;

Butane-1-sulfonic acid--(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3yl)-amide;

- 2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide;
- 3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide;
- 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide;
- 30 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide;

```
3-(2-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
            3-(3-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
            3-(4-Nitro-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
            3-(2-Methoxy-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
 5
            3-(3-Methoxy-benzylamino)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
            5-Phenyl-3-(2-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-
     one;
            5-Phenyl-3-(3-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-
     one;
            5-Phenyl-3-(4-trifluoromethyl-benzylamino)-1,3-dihydro-benzo[e][1,4]diazepin-2-
10
     one;
            3-[(Furan-2-ylmethyl)-amino]-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;
            N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;
            N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-
15
     isobutyramide;
            N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-
     methanesulfonamide;
            Furan-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]
      diazepin-3-yl)-amide;
             Thiophene-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e]
20
      [1,4]diazepin-3-yl)-amide;
             Cyclohexanecarboxylic acid (7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e]
      [1,4]diazepin-3-yl)-amide;
             N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-
      methoxy-benzamide;
25
             N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-
      methoxy-benzamide;
             N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-nitro-
      benzamide;
             2-(2-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]
30
      diazepin-3-yl)-acetamide;
```

```
2-(3-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-acetamide;
```

- 2-(4-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-acetamide;
- 5 2-(4-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;
 - 2-(3-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acetamide;
- N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(2trifluoromethyl-phenyl)-acetamide;
 - N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(3-trifluoromethyl-phenyl)-acetamide;
 - N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(4-trifluoromethyl-phenyl)-acetamide;
- 15 1-(2-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;
 - 1-(2-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
 - 1-(2-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-
- 20 urea;
 - 1-(4-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
 - 1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-p-tolyl-urea;
 - 1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-
- 25 urea;
 - 1-(4-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
 - (S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;
- 4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-benzamide;

- (S)- 4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 5 (S)- 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;
 - 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- (S)- 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-10 1H-benzo[e][1,4]diazepin-3-yl)-amide;
 - (S)-2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethyl-benzamide;
 - 2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 15 (S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 2-Hydroxy- N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- (S)-2-Hydroxy- N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-20 benzamide;
 - 1H-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;
 - (S)-1H-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-amide;
- 3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
 - (S)-3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;
- N-[7-Chloro-5-(2-fluoro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepine-3-30 yl]-4-methoxoy-benzamide;

67

- 1-(2-Fluoro-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- 1-(4-Methoxy-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;
- 5 1-(3-Methyl-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
 - 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethyl-phenyl)-urea;
- 4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-10 yl)-benzamide;
 - 4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide;
 - 3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide;
 - 5-Fluoro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 3-(2-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)propionamide;

- 3-(3-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-propionamide;
- 3-(4-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-propionamide;

WO 2005/089769

- N-[5-(3-Chloro-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-methoxy-benzamide;
- N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxy-benzamide;
- N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-nitro-benzamide;
 - N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitro-benzamide;
 - 4-Methoxy-N-[2-oxo-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl]-benzamide;
 - 2-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl]-benzamide;
 - 4-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl]-benzamide;
- 2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 2-Methoxy-N-[5-(3-mehtoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl]-benzamide
 - N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl]-4-nitro-benzamide;
- 25 2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;
- 2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-30 benzamide;

- (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid benzyl ester;
- 1-(3,5-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;
- 5 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethoxy-phenyl)-urea;
 - 1-(4-Bromo-2-trifluoromethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- 1-(4-Bromo-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-10 urea;
 - 1-(2,3-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;
 - 1-(2,6-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;
- 1-(2-Chloro-6-methyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-urea;
 - 1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- 1-(2-Methylsulfanyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] 20 diazepin-3-yl)-urea;
 - 1-(2,6-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;
 - 5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;
- 25 2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 1-(2,6-Difluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea;
- 1-(3-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-30 urea;
 - 1-(3-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]

70

```
diazepin-3-yl)-urea;
```

- 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(3-trifluoromethyl-phenyl)-urea;
- 1-(3-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
 - 2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;
 - 4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide:
- N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester;
 - 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-propoxybenzamide;
 - 2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
 - 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-terephthalamic acid methyl ester;
- 4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-benzamide;
 - 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-m-tolyl-urea;
 - 2-Methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide;
- 25 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sulfamoyl-benzamide;
 - 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-propionamide
- 3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-30 phenyl-propionamide;
 - 3-(2-Fluoro-phenyl)-1-methyl-1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]

diazepin-3-yl)-urea;

5

15

20

25

2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-benzamide;

1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

- 1-Cycloheyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- 1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- 1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;
- 4,5-Dimethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)amide;
- Piperidine-1-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-amide;
 - N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide;
 - N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-isobutyramide;
 - Furan-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;
 - Thiophene-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;
 - Cyclohexanecarboxylic acid [5-(3chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;
 - Piperidine-1-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;
 - N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide;
 - 5-Methyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;
 - Pyrazine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;
- N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl]-isobutyramide;

5

10

20

25

Thiophene-2-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Piperidine-1-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-amide;

Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-amide;

Thiophene-2-carboxylic acid (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-thiophene-2-ylurea;

1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-thiophene-3-ylurea;

Pyridine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

1H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-amide;

6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-nicotinamide;

2-Ethoxy-naphthalene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

9-Oxo-9H-fluorene-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-amide;

2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide;

(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl as ester;

WO 2005/089769

PCT/GB2005/001018

- (S)-4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1Hbenzo[e][1,4]diazepin-3-yl)-amide;
- (S)-Benzofuran-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl)-amide;
- 5 (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid methyl ester;
 - (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid ethyl ester;
- (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid isobutyl 10 ester; and
 - 2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-thiophene-2-yl-acetamide.
- 21. A composition according to any one of claims 2 to 20, wherein the benzodiazepine 15 derivative of formula (V) is 1-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1Hbenzo[e][1,4]diazepin-3-yl)-urea, 2-methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1Hbenzo[e][1,4]diazepin-3-yl)-benzamide or 4-methanesulfonyl-2-methoxy-N-(2-oxo-5phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-benzamide.
- A composition according to claim 21, wherein the benzodiazepine derivative of 20 22. formula (V) is 1-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl)-urea.
- 23. A composition according to any one of the preceding claims wherein component 25 (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof,

$$R_2$$
 R_3
 R_2
 R_3
 R_1
 R_3
 R_3
 R_4
 R_5
 R_5
 R_5
 R_7
 R_7

wherein:

- X is a direct link or C₁₋₆ alkyl; said C₁₋₆ alkyl being optionally substituted with halogen, oxo, cyano, hydroxyl, OCOR₄ or S(O)n-C₁₋₆ alkyl;

- Y is R_4 , NR_4R_5 , $NCOR_4$, =N-OR₄, -CONHR₄, COOR₄, -OR₄, aryl, heteroaryl, cyclyl or heterocyclyl, where R_4 and R_5 are H or C_{1-6} alkyl;
- Z is CR_6R_7 , where R_6 and R_7 are independently H, or straight, branched or cyclic C_{1-6} alkyl;
- 10 n is 1-2;
 - R₁ is CONR₄R₅, CO₂R₄ or C₁₋₆ alkyl, said C₁₋₆ alkyl can be optionally substituted with OR₄ or NR₈R₉;
 - R₈ and R₉ are each independently H, C₁₋₆ alkyl, SO₂R₅, CO₂R₄ or COR₄;
- R₂ is selected from the group consisting of NH₂, CONR₆R₇, heteroaryl, C₂₋₆ alkenyl,

 CO₂R₄, N=CPh₂, C(=NH)NH₂ and C₁₋₆ alkyl; said alkyl optionally substituted with a member selected from the group consisting of halogen, CN, NR₁₀R₁₁, OSO2R₄ and OR₄;
 - R₁₀ and R₁₁ are each independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, CO₂R₄, COR₄ and SO₂R₄;
- R₃ is selected from the group consisting of (1) CO₂R₉; (2) C₁₋₆ alkyl optionally substituted with CN, OR₄ or NR₆R₇; and (3) C₂₋₆ alkenyl substituted with CN;
 - Q is a member selected from the group consisting of

75

A is C or N, optionally substituted with H, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, cyano-C₁₋₆ alkyl, CO₂R₄, aryl, benzoaminocarbonyl, hydroxybenzyl, SO₂NR₄R₅ or C₃₋₆ cycloalkyl.

Where A is carbon, it may also be optionally substituted by O or S via a double bond;

B is C or N; where B is C it may be optionally substituted by H, C₁₋₆ alkyl, NO₂, CN, halogen, COR₄, COOR₄, CONHR₄C(=NH)NH₂ or C(=NOH)NH₂.

24. A composition according to any of claims 1 to 22, wherein component (a) is a compound of the formula (I), as defined above or a pharmaceutically acceptable salt thereof, wherein at least two of R₁, R₂ and R₃ are hydrogen, and the other is hydrogen or -C(NH)-NH₂ and/or either -X-Y is H, or X is a C₁-C₆ alkylene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, -NR'R'', -COR', -SO₂R' or phenyl, wherein R' and R'' are the same or different and represent a C₁-C₄ alkyl group and/or Z is -CH₂- and/or Q is a moiety

wherein B is -CH- or -N-, A₁ is -C(O)- or -NH- and A₂ is -CH₂-, -CHR'- or -NR"-, wherein R' is a halogen atom and R" represents a hydrogen atom or a C₁-C₄ alkyl, C₂-C₄ alkenyl, C₃-C₆ cycloalkyl, -SO₂-(C₁-C₆ alkyl), -SO₂-N(C₁-C₆ alkyl)₂ or -(CO-NH)_a-(C₁-C₄ alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent.

5

10

25. A composition according to any of claims 1 to 22, wherein component (a) is a compound of the formula (II), or a pharmaceutically acceptable salt thereof

wherein:

5 - L_1 is -CH₂- or -CHR₂-CO-

- each X is the same or different and is CH or N;

- each R_1 is the same or different and is C_{1-6} alkyl, halogen, hydroxy, phenyl or $(CH_2)_m=NH_2$;
- n is 1 or 2;

10 - R_2 is C_{1-6} alkoxy or C_{1-6} alkoxy-phenyl;

- R_3 is C_{1-6} alkyl;
- L_2 is -CH₂- or -NH-;
- Y is C_{1-6} alkyl or C_{1-6} alkenyl;
- Z is H, N(R₄)₂-, -C(=O)-R₅, -C(=CH₂)-R₅, -CH(OH)-R₅, -CH(CH₃)-R₅, -CH(OCH₃)-R₅;

- each R₄ is the same or different and is H, C₁₋₆ alkyl.

- R_5 is C_{1-6} alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl; and
- m=1-6

20

15

26. A composition according to anyone of claims 1 to 22, wherein component (a) is: 1-Cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydroimidazo[4,5-c]pyridin-2-one

10

- {2-[2-(1,2-Dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]]ethyl}-diethylamine
- {2-[2-(3-Iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine
- 5 1-Isopropenyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydrobenzoimidazol-2-one
 - 1-(4-Hydroxy-benzyl)-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one
 - 1-Isopropenyl-3-[1-(3-oxo-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one
 - 1-Ethyl-3-[1-(2-hydroxy-2-phenyl-ethyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one
 - 1-Ethyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydrobenzoimidazol-2-one
- 7-[2-(3-Isopropenyl-2-oxo-2,3-dihydrobenzoimidazol-1-ylmethyl)-benzoimidazol-1-yl]-heptanenitril
 - 5-{3-[1-(3-Methanesulfonyl-propyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-yl}-pentanenitrile
 - 3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-1-carboxylic acid benzylamide
 - 1-Methanesulfonyl-3-[1-(3-methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one
 - 3-[1-(3-Methyl-butyl)-1H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydrobenzoimidazol-1-sulfonic acid dimethylamide
- 25 1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one
 - Bis(5-amidino-2-benzimidazolyl)-methane
 - 2-{2-[1-[1-(2-Amino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol-1-ylmethyl}-6-methyl-pyridin-3-ol
- or a pharmaceutically acceptable salt thereof.

78

- 27. A composition according to any one of claims 1 to 22, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazo[4,5-c]pyridin-2-one, {2-[2-(1,2-dihydro-benzotriazol-1-ylmethyl)-benzoimidazol-1-yl]]ethyl}-diethyl-amine, {2-[2-(3-iodo-2,3-dihydro-indazol-1-ylmethyl)-benzimidazol-1-yl]-ethyl}-dimethyl-amine or a pharmaceutically acceptable salt thereof.
- 28. A composition according to any one of claims 1 to 22, wherein component (a) is 1-cyclopropyl-3-[1-(4-hydroxy-butyl)-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-imidazol4,5-c]pyridin-2-one or 1-Isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazol4,5-c]pyridine-2-one or a pharmaceutically acceptable salt thereof.
- 29. A composition according to any one of the preceding claims wherein component (a) is present in an amount of from 0.025 wt% to 10 wt%.
- 15 30. A composition according to any one of the preceding claims wherein component (b) is present in an amount of 0.025 wt% to 10 wt%.
 - 31. A composition according to any one of the preceding claims, for use in the treatment of the human or animal body.

32. Use of:

5

10

- (a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28; and
- (b) a benzodiazepine derivative defined in any one of claims 1 to 22,
 25 in the manufacture of a medicament for use in treating or preventing an RSV infection.
 - 33. Use according to claim 31, wherein the medicament is a composition as defined in claim 29 or 30.
- 30 34. A product comprising:

WO 2005/089769

79

PCT/GB2005/001018

- (a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28; and
- (b) a benzodiazepine derivative as defined in any one of claims 1 to 22; for separate, simultaneous or sequential use in the treatment of the human or animal body.

- 35. A product according to claim 34 for separate, simultaneous or sequential use in treating or preventing an RSV infection.
- 36. A method of treating or preventing an RSV infection in a patient, which method comprises the administration to said patient of:
 - (a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28; and
 - (b) a benzodiazepine derivative as defined in any one of claims 1 to 22.
- 15 37. Use of an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a benzodiazepine derivative as defined in any one of claims 1 to 22.
- 38. Use of a benzodiazepine derivative as defined in any one of claims 1 to 22, in the manufacture of a medicament for use in treating or preventing an RSV infection, by coadministration with an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28.